Skip to the beginning of the images gallery

Cemiplimab (anti-PD-1), for ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt various applications, specific to PDCD1, >95%, high purity, Human IgG4, Antibody of programmed cell death 1 (CD279)

Azide Free
Carrier Free
ExactAb™
Low Endotoxin
Recombinant
Validated
≥95%(SDS-PAGE&SEC)
Lot by Lot

Features and benefits

Short Overview:
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Application: ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
Species reactivity(Reacts with): Human
Isotype: Human IgG4

Application:

Animal Model
ELISA
Flow Cytometry
Functional Assay

Item Number

C412010

Grouped product items
SKU	Size	Availability	Price
C412010-100μg	100μg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$99.90
C412010-1mg	1mg	In stock	$453.90
C412010-5mg	5mg	In stock	$1,889.90
C412010-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$3,401.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series

Accession#:Q15116 Gene ID:5133 PD1 PDCD1 programmed cell death 1 (CD279) Antibody

Basic Description

Product Name	Cemiplimab (anti-PD-1), for ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt various applications, specific to PDCD1, >95%, high purity, Human IgG4
Synonyms	Libtayo; REGN-2810; cemiplimab-rwlc; CD279 antigen; CD279; hPD-1; PD1; PD-1; PD1hPD-l; PDCD1; programmed cell death 1; programmed cell death protein 1; Protein PD-1; SLEB2; CD279 antibody; CD279 antigen antibody; hPD 1 antibody; hPD l antibody; hPD-1 anti
Specifications & Purity	ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Specificity	PDCD1
Application	ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type	INHIBITOR
Mechanism of action	Antibody of programmed cell death 1 (CD279)
Product Description	Cemiplimab is a monoclonal IgG4 antibody with high affinity for programmed death receptor-1 (PD-1) that blocks PD-1/PD-L1 mediated T cell inhibition. It is commonly used in squamous cell skin cancer research. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg

Product Properties

Antibody Type	Primary antibody
Clonality	Recombinant
Isotype	Human IgG4
Light Chain Type	kappa
SDS-PAGE	26.0 kDa (Light Chain) & 49.9 kDa (Heavy Chain), under reducing conditions; 169.6 kDa, under non-reducing conditions.
Purification Method	Protein A purified
Purity	>95%
Source	CHO supernatant
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	1801342-60-8

Images

Cemiplimab (anti-PD-1) (C412010) - ELISA
Immobilized hu-PD-1 at 2 μg/mL can bind Cemiplimab (anti-PD-1) (C412010) with the EC₅₀ of 8.66 ng/mL.

Cemiplimab (anti-PD-1) (C412010) - SEC
The purity of Cemiplimab (anti-PD-1) (C412010) is more than 95% verified by HPLC.

Cemiplimab (anti-PD-1) (C412010) - ELISA
Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Cemiplimab (anti-PD-1) (C412010) with the EC50 of 12.82 ng/mL.

IMGT/mAb-DB

846

Reactome Reaction

R-HSA-9679421

Reactome Drug

R-ALL-9679434

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot Number	Certificate Type	Date	Item
ZJ23F1202079	Certificate of Analysis	Dec 20, 2023	C412010
ZJ23F1202078	Certificate of Analysis	Dec 20, 2023	C412010

References

1. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M et al.. (2014) Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.. Proc Natl Acad Sci USA, 111 (14): (5153-8). [PMID:24706856]
2. Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG. (2016) Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.. J Immunother Cancer, 4 (3): (70). [PMID:27879972]
3. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017) Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.. Mol Cancer Ther, 16 (5): (861-870). [PMID:28265006]
4. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS et al.. (2018) PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.. N Engl J Med, 379 (4): (341-351). [PMID:29863979]
5. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334]
6. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039]
7. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.. Curr Opin Investig Drugs, 11 (12): (1354-9). [PMID:21154117]
8. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer Control, 20 (1): (22-31). [PMID:23302904]
9. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.. Structure, 23 (12): (2341-2348). [PMID:26602187]
10. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips. (1997-10-23) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.. Gene, 197 ((1-2)): (177-187). [PMID:9332365]
11. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J.. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.. J Med Chem, 63 (15): (8338-8358). [PMID:32667799]
12. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T.. (1994) Structure and chromosomal localization of the human PD-1 gene (PDCD1).. Genomics, [PMID:7851902]
13. Prokunina, Ludmila L and 23 more authors.. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.. Nature genetics, [PMID:12402038]
14. Fife, Brian T BT and Pauken, Kristen E KE.. (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance.. Annals of the New York Academy of Sciences, [PMID:21276005]
15. Topalian, Suzanne L SL and 29 more authors.. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.. The New England journal of medicine, (28): [PMID:22658127]
16. Cheng, Xiaoxiao X and 18 more authors.. (2013) Structure and interactions of the human programmed cell death 1 receptor.. The Journal of biological chemistry, (26): [PMID:23417675]
17. Robert, Caroline C and 27 more authors.. (2015) Nivolumab in previously untreated melanoma without BRAF mutation.. The New England journal of medicine, (22): [PMID:25399552]
18. McDermott, J J and Jimeno, A A.. (2015) Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.. Drugs of today (Barcelona, Spain : 1998), [PMID:25685857]
19. Na, Zhenkun and 6 more authors.. (2017) Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.. Cell research, [PMID:27325296]
20. Pascolutti, Roberta R and 6 more authors.. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.. Structure (London, England : 1993), (4): [PMID:27618663]
21. Horita, Shoichiro S and 5 more authors.. (2016) High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.. Scientific reports, (13): [PMID:27734966]
22. Tan, Shuguang S and 15 more authors.. (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.. Nature communications, (6): [PMID:28165004]
23. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ.. (2018) PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.. Gene, (5): [PMID:28951311]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Cemiplimab (anti-PD-1), for ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt various applications, specific to PDCD1, >95%, high purity, Human IgG4, Antibody of programmed cell death 1 (CD279)

Basic Description

Product Properties

Images

Associated Targets

PDCD1 Tclin Programmed cell death protein 1 0 Activities

Database links